# Colony Stimulating Factors

This is a subcategory of Blood Formation, Coagulation, and Thrombosis Agents.

## Formulary

### Preferred

| Preferred    | Generic Name | Quantity | Time (Days) |
| :----------- | :----------- | :------: | :---------: |
| Neupogen PA  |              |          |             |
| Releuko PA   |              |          |             |
| Ziextenzo PA |              |          |             |

### Non-Preferred

| Non-Preferred    | Generic Name | Quantity | Time (Days) |
| :--------------- | :----------- | :------: | :---------: |
| Fulphila      |  |              |          |             |
| Granix        |  |              |          |             |
| Leukine       |  |              |          |             |
| Neulasta      |  |              |          |             |
| Nivestym      |  |              |          |             |
| Nyvepria      |  |              |          |             |
| Udenyca       |  |              |          |             |
| Zarxio        |  |              |          |             |

## Length of Authorizations

Approval based upon diagnosis below:

| Diagnosis  | Approval Length |
|---|---|
| Acute Myeloid Leukemia (AML) | 14 days or duration of chemotherapy regimen |
| Malignancy at risk for febrile neutropenia or undergoing myeloablative chemotherapy prior to allogeneic or autologous bone marrow transplantation | 14 days or duration of chemotherapy regimen |
| Myeloid Engraftment for bone marrow transplant (BMT) | 30 days |
| Severe, chronic neutropenia with absolute neutrophil count (ANC) of less than 500/mm3 and have symptoms associated with neutropenia (e.g. fever, infections, oropharyngeal ulcers). | 30 days |
| Hematopoietic radiation injury syndrome | 30 days |

### All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Additional Criteria

### Non-Preferred

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least **14 days** with at least **one preferred** drug
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

-   Must provide documentation of patientâ€™s clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=10)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=8)
